AGC
TAK icon

Aspen Grove Capital’s Takeda Pharmaceutical TAK Stock Holding History

Aspen Grove Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,146
Closed -$134K – 218
2024
Q2 		$134K Sell
10,146
-50
-0.5% -$662 0.03% 201
2024
Q1 		$142K Buy
10,196
+86
+0.9% +$1.25K 0.04% 201
2023
Q4 		$144K Buy
+10,110
New +$143K 0.04% 184
2023
Q3 		– Sell
-10,310
Closed -$165K – 205
2023
Q2 		$165K Sell
10,310
-920
-8% -$15.1K 0.05% 185
2023
Q1 		$185K Buy
11,230
+1,078
+11% +$17.2K 0.08% 140
2022
Q4 		$158K Buy
+10,152
New +$142K 0.07% 152

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Aspen Grove Capital's TAK Position: Q3 2024 in Review

Aspen Grove Capital sold out of Takeda Pharmaceutical (TAK) in Q3 2024, closing a stake of 10,146 shares — an estimated $134K sold.

Aspen Grove Capital first reported a position in TAK in Q4 2022 and held it in 6 quarters. The position peaked at $185K in Q1 2023. 298 funds tracked by Wall St. Rank hold TAK as of Q3 2024.

  • Aspen Grove Capital reported no remaining Takeda Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Aspen Grove Capital sold 10,146 Takeda Pharmaceutical shares in Q3 2024, an estimated $134K.
  • Aspen Grove Capital first reported a position in Takeda Pharmaceutical in Q4 2022 and held it in 6 quarters.
  • Aspen Grove Capital's Takeda Pharmaceutical position peaked at $185K in Q1 2023.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2024.

Based on Aspen Grove Capital's 13F filing for Q3 2024, filed 13 Nov 2024.